CLINICAL_TRIALS
trial_result
· 2019-06-27
Clinical Trial Update: Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy [Phase 2]
Summary
Phase 2 clinical trial update for fostamatinib in IgA nephropathy reports safety and efficacy data.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Rigel Pharmaceuticals | Conditions: IGA Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2019-06-27